TWI747178B - 單鏈trail-受體激動劑蛋白質 - Google Patents

單鏈trail-受體激動劑蛋白質 Download PDF

Info

Publication number
TWI747178B
TWI747178B TW109106778A TW109106778A TWI747178B TW I747178 B TWI747178 B TW I747178B TW 109106778 A TW109106778 A TW 109106778A TW 109106778 A TW109106778 A TW 109106778A TW I747178 B TWI747178 B TW I747178B
Authority
TW
Taiwan
Prior art keywords
trail
receptor agonist
seq
domain
protein
Prior art date
Application number
TW109106778A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024123A (zh
Inventor
奧利維 希爾
克利斯汀安 吉佛司
曼諾夫 希爾曼
福瑞茲 Ｇ 布恰南
戴倫 Ｃ 菲利浦
蘇珊 E 萊普
Original Assignee
德商阿波吉尼克斯公司
美商艾伯維有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商阿波吉尼克斯公司, 美商艾伯維有限公司 filed Critical 德商阿波吉尼克斯公司
Publication of TW202024123A publication Critical patent/TW202024123A/zh
Application granted granted Critical
Publication of TWI747178B publication Critical patent/TWI747178B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
TW109106778A 2014-04-23 2015-04-23 單鏈trail-受體激動劑蛋白質 TWI747178B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
US61/983,152 2014-04-23

Publications (2)

Publication Number Publication Date
TW202024123A TW202024123A (zh) 2020-07-01
TWI747178B true TWI747178B (zh) 2021-11-21

Family

ID=53055121

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109106778A TWI747178B (zh) 2014-04-23 2015-04-23 單鏈trail-受體激動劑蛋白質
TW104113087A TWI683825B (zh) 2014-04-23 2015-04-23 單鏈ｔｒａｉｌ-受體激動劑蛋白質

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104113087A TWI683825B (zh) 2014-04-23 2015-04-23 單鏈ｔｒａｉｌ-受體激動劑蛋白質

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3366699A1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR102079919B1 (enExample)
CN (2) CN111718424A (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA3184067A1 (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA45069A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG10201806465TA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI747178B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138585A (ko) 2015-05-04 2017-12-15 아포게닉스 아게 단일-쇄 cd40-수용체 작용제 단백질
WO2017068192A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd27-receptor agonist proteins
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
CN108699129A (zh) * 2015-10-23 2018-10-23 阿珀吉科吉尼科斯股份公司 单链light受体激动剂蛋白
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
US10821160B2 (en) 2016-03-01 2020-11-03 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
MX2018011219A (es) * 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN109641033A (zh) * 2016-06-13 2019-04-16 梅里麦克制药股份有限公司 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
JP7744621B2 (ja) * 2017-08-11 2025-09-26 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
EP4346885A1 (en) 2021-05-28 2024-04-10 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025984A1 (es) 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
HU230603B1 (hu) 2000-12-07 2017-03-28 Eli Lilly And Company GLP1 fúziós fehérjék
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
ES2333358T3 (es) 2005-04-15 2010-02-19 Rappaport Family Institute For Research In The Medical Sciences Moleculas y metodos de uso de las mismas para el tratamiento de enfermedades asociadas con mcp-1/ccr2.
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP2484691B1 (en) 2007-07-10 2016-01-13 Apogenix GmbH TNF superfamily collectin fusion proteins
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2011002759A (es) 2008-09-22 2011-07-28 Amgen Inc Metodo de tratamiento.
WO2010042890A2 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
EP2829550B1 (en) 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
WO2010085682A2 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
JP2013514795A (ja) * 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
MX341119B (es) 2010-04-13 2016-08-09 Medimmune Llc Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail).
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
ES2924109T3 (es) 2012-07-18 2022-10-04 Apogenix Ag Composición que comprende una mezcla de isoformas de CD95-Fc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules

Also Published As

Publication number Publication date
WO2015164588A1 (en) 2015-10-29
TWI683825B (zh) 2020-02-01
AU2015249649A1 (en) 2016-11-10
BR112016024515B1 (pt) 2020-03-31
AU2015249649B2 (en) 2018-10-04
CA2946402A1 (en) 2015-10-29
RU2016145608A (ru) 2018-05-28
HRP20180950T1 (hr) 2018-08-10
JP6714751B2 (ja) 2020-06-24
JP2017513503A (ja) 2017-06-01
TR201806912T4 (tr) 2018-06-21
AR100168A1 (es) 2016-09-14
SG10202111785VA (en) 2021-12-30
KR102079919B1 (ko) 2020-02-24
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
DOP2016000284A (es) 2017-02-15
EP3366699A1 (en) 2018-08-29
SG10201806465TA (en) 2018-08-30
RU2016145608A3 (enExample) 2018-12-26
HUE038914T2 (hu) 2018-12-28
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
IL272612A (en) 2020-03-31
MX2016013858A (es) 2017-08-02
JP2019162114A (ja) 2019-09-26
US9908927B2 (en) 2018-03-06
NZ725476A (en) 2023-09-29
RU2699285C2 (ru) 2019-09-04
MA39770A (fr) 2015-10-29
US20250145688A1 (en) 2025-05-08
PH12020500377A1 (en) 2022-11-14
KR20170012257A (ko) 2017-02-02
US20180222962A1 (en) 2018-08-09
SMT201800286T1 (it) 2018-07-17
SG11201608767XA (en) 2016-11-29
MX2019013587A (es) 2020-01-13
US20150337027A1 (en) 2015-11-26
LT3134430T (lt) 2018-05-10
TW202024123A (zh) 2020-07-01
UA118286C2 (uk) 2018-12-26
AU2018271369A1 (en) 2018-12-20
EP3134430B1 (en) 2018-03-21
DK3134430T3 (en) 2018-05-22
ECSP16089579A (es) 2018-05-31
NO2776305T3 (enExample) 2018-01-27
CY1120281T1 (el) 2019-07-10
KR20190135546A (ko) 2019-12-06
CN106459221B (zh) 2020-09-01
CR20160516A (es) 2017-05-10
PT3134430T (pt) 2018-04-20
PH12016502079B1 (en) 2016-12-19
CL2016002683A1 (es) 2017-07-07
PL3134430T3 (pl) 2018-08-31
CA2946402C (en) 2023-02-28
MA45069A (fr) 2019-04-03
US20240174731A1 (en) 2024-05-30
EP3134430A1 (en) 2017-03-01
PH12016502079A1 (en) 2016-12-19
US20210040178A1 (en) 2021-02-11
UY36095A (es) 2015-10-30
IL248244B (en) 2020-03-31
TW201620928A (zh) 2016-06-16
RS57153B1 (sr) 2018-07-31
JP6523331B2 (ja) 2019-05-29
AU2020202247A1 (en) 2020-04-23
IL248244A0 (en) 2016-11-30
MY181986A (en) 2021-01-18
PE20170299A1 (es) 2017-05-06
BR112016024515A2 (pt) 2017-10-10
SI3134430T1 (en) 2018-05-31
ES2672368T3 (es) 2018-06-14

Similar Documents

Publication Publication Date Title
TWI747178B (zh) 單鏈trail-受體激動劑蛋白質
ES2754432T3 (es) Proteínas agonistas de receptor CD40 de cadena sencilla
US10844108B2 (en) Single-chain CD27-receptor agonist proteins
US20210246190A1 (en) Single-chain cd137-receptor agonist proteins
US10683332B2 (en) Single-chain light receptor agonist proteins
US11149075B2 (en) Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins
US20180230196A1 (en) Single-chain ox40-receptor agonist proteins
HK1260151A1 (en) Single-chain trail-receptor agonist proteins
NZ725476B2 (en) Single-chain trail-receptor agonist proteins
HK1235072A1 (en) Single-chain trail-receptor agonist proteins
HK1235072B (en) Single-chain trail-receptor agonist proteins

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees